VentureDNA | Immunicom
16597
single,single-portfolio_page,postid-16597,ajax_fade,page_not_loaded,,qode-theme-ver-6.3,wpb-js-composer js-comp-ver-4.3.5,vc_responsive

Immunicom

About This Project

Immunicom leverages the latest clinical research in immune regulatory pathways and their relationship with cancer and autoimmune disease. Using its proprietary Immunopheresis(tm) approach, Immunicom has developed a unique therapeutic delivery method for its immune regulatory proteins. This method minimizes, and in some cases eliminates, the severe side effects associated with cancer and autoimmune treatments. As a lead Investor, VentureDNA will be providing growth capital, while advising the senior management team on operation and strategic initiatives. www.immunicom.com

Industry

Healthcare

Date

November 2016

Category
Consulting, Investment